Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 1.01, 117 Camberwell Rd, Hawthorn East VIC 3123, Australia 19 October 2026 ASX Announcement USAMRIID Marburg NHP study advances as 22 non-human primates successfully complete screening • Screening and preparation...
USAMRIID Marburg study advances towards dosing
Filed with ASX · · 3 pages · English
Release
Island Pharmaceuticals Ltd on 6ix
Story so far
Earlier from Island Pharmaceuticals
- Notification regarding unquoted securities - ILA
- Galidesivir GMP manufacturing commences
- Annual General Meeting - Rescheduled Date
- Pivotal Marburg data secured for Galidesivir FDA pathway
- Appendix 4G and Corporate Governance Statement
Later from Island Pharmaceuticals
- Letter to Shareholders, Notice of AGM & Proxy Form
- Quarterly Appendix 4C and Activities Report
- NHP Surgeries Commence Ahead of Galidesivir Marburg Study
- Investor webinar
- Investor webinar presentation
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals